11/19
09:15 am
fblg
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
Medium
Report
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
11/14
09:15 am
fblg
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
High
Report
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
11/13
08:05 am
fblg
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Low
Report
FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/12
04:32 pm
fblg
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
04:20 pm
fblg
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/30
07:27 am
fblg
FibroBiologics, Inc. (NASDAQ: FBLG) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $12.00 price target on the stock.
Medium
Report
FibroBiologics, Inc. (NASDAQ: FBLG) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $12.00 price target on the stock.
10/29
09:15 am
fblg
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
Low
Report
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
10/28
09:31 am
fblg
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
Low
Report
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
10/18
08:30 am
fblg
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
Medium
Report
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
10/16
09:15 am
fblg
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
Medium
Report
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
10/11
09:31 am
fblg
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
High
Report
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
9/30
09:31 am
fblg
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
Medium
Report
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
9/24
08:06 am
fblg
FibroBiologics, Inc. (NASDAQ: FBLG) is now covered by analysts at Maxim Group. They set a "buy" rating and a $12.00 price target on the stock.
Low
Report
FibroBiologics, Inc. (NASDAQ: FBLG) is now covered by analysts at Maxim Group. They set a "buy" rating and a $12.00 price target on the stock.
9/19
09:31 am
fblg
FibroBiologics Engages Southern Star Research as CRO in Australia
Medium
Report
FibroBiologics Engages Southern Star Research as CRO in Australia
9/12
09:31 am
fblg
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
Medium
Report
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
9/6
09:31 am
fblg
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
High
Report
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
9/6
06:59 am
fblg
FibroBiologics, Inc. (NASDAQ: FBLG) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
High
Report
FibroBiologics, Inc. (NASDAQ: FBLG) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.